PTCT Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients.
- FDA lifts PTC518 partial clinical hold based on PIVOT-HD data
| 发布于: | 雪球 | 转发：0 | 回复：0 | 喜欢：0 |
PTCT Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients.
- FDA lifts PTC518 partial clinical hold based on PIVOT-HD data